AAIC 2025 Abstract
Baseline Imaging Characteristics of Participants in the Phase II/III DIAN‐TU‐001 Tau NexGen Trial for Dominantly Inherited Alzheimer’s Disease
By Tammie L.S. Benzinger, Arnaud Charil, Brian Andrew Gordon, Show 7 more authorsRandall John Bateman
Trial in peoplePopulations
Abstract
Background: The DIAN‐TU‐001 trial, conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN‐TU) at Washington University in St Louis, in collaboration with Eisai, is a study arm of the Tau NexGen platform study.
